Adam J. Kundishora

Adam J. Kundishora

Auto-generated profile, based on publicly available information

Adam J. Kundishora

Division of Neurosurgery, Department of Surgery, Children's Hospital of Philadelphia, Philadelphia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CMCian McCafferty
Cian McCafferty
BGBenjamin Fredrick Gruenbaum
Benjamin Fredrick Gruenbaum
RTRenee Tung
Renee Tung
JLJing-Jing Li
Jing-Jing Li
XZXinyuan Zheng
Xinyuan Zheng
HBHal Blumenfeld
Hal Blumenfeld
Absence seizures are brief episodes of impaired consciousness, behavioral arrest, and unresponsiveness, with yet-unknown neuronal mechanisms. Here we report that an awake female rat model recapitulates the behavioral, electroencephalographic, and cortical functional magnetic resonance imaging characteristics of human absence seizures. Neuronally, seizures feature overall decreased but rhythmic firing of neurons in cortex and thalamus. Individual cortical and thalamic neurons express one of four distinct patterns of seizure-associated activity, one of which causes a transient initial peak in overall firing at seizure onset, and another which drives sustained decreases in overall firing. 40–60 s before seizure onset there begins a decline in low frequency electroencephalographic activity, neuronal firing, and behavior, but an increase in higher frequency electroencephalography and rhythmicity of neuronal firing. Our findings demonstrate that prolonged brain state changes precede consciousness-impairing seizures, and that during seizures distinct functional groups of cortical and thalamic neurons produce an overall transient firing increase followed by a sustained firing decrease, and increased rhythmicity.

17 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZShujuan Zhao
Shujuan Zhao
KMKedous Y. Mekbib
Kedous Y. Mekbib
MEMartijn A. van der Ent
Martijn A. van der Ent
Garrett AllingtonGarrett Allington
Garrett Allington
APAndrew Prendergast
Andrew Prendergast
Kristopher T. KahleKristopher T. Kahle
Kristopher T. Kahle
To elucidate the pathogenesis of vein of Galen malformations (VOGMs), the most common and most severe of congenital brain arteriovenous malformations, we performed an integrated analysis of 310 VOGM proband-family exomes and 336,326 human cerebrovasculature single-cell transcriptomes. We found the Ras suppressor p120 RasGAP (RASA1) harbored a genome-wide significant burden of loss-of-function de novo variants (2042.5-fold, p = 4.79 x 10−7). Rare, damaging transmitted variants were enriched in Ephrin receptor-B4 (EPHB4) (17.5-fold, p = 1.22 x 10−5), which cooperates with p120 RasGAP to regulate vascular development. Additional probands had damaging variants in ACVRL1, NOTCH1, ITGB1, and PTPN11. ACVRL1 variants were also identified in a multi-generational VOGM pedigree. Integrative genomic analysis defined developing endothelial cells as a likely spatio-temporal locus of VOGM pathophysiology. Mice expressing a VOGM-specific EPHB4 kinase-domain missense variant (Phe867Leu) exhibited disrupted developmental angiogenesis and impaired hierarchical development of arterial-capillary-venous networks, but only in the presence of a “second-hit” allele. These results illuminate human arterio-venous development and VOGM pathobiology and have implications for patients and their families.

7 July 2021 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
AKAdam J. Kundishora
Adam J. Kundishora
ASAmrita K. Singh
Amrita K. Singh
Garrett AllingtonGarrett Allington
Garrett Allington
PDPhan Q. Duy
Phan Q. Duy
JRJian Ryou
Jian Ryou
Kristopher T. KahleKristopher T. Kahle
Kristopher T. Kahle

6 March 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AKAdam J. Kundishora
Adam J. Kundishora
Garrett AllingtonGarrett Allington
Garrett Allington
SMStephen McGee
Stephen McGee
KMKedous Y. Mekbib
Kedous Y. Mekbib
VGVladimir Gainullin
Vladimir Gainullin
Kristopher T. KahleKristopher T. Kahle
Kristopher T. Kahle

11 January 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AKAdam J. Kundishora
Adam J. Kundishora
BRB.A. Benjamin Reeves
B.A. Benjamin Reeves
CNCarol Nelson‐Williams
Carol Nelson‐Williams
CHChristopher S. Hong
Christopher S. Hong
PGPallavi P. Gopal
Pallavi P. Gopal
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay

1 June 2020 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
CHChristopher S. Hong
Christopher S. Hong
JVJuan C. Vasquez
Juan C. Vasquez
AKAdam J. Kundishora
Adam J. Kundishora
AEAladine A. Elsamadicy
Aladine A. Elsamadicy
JBJason M. Beckta
Jason M. Beckta
EOE. Zeynep Erson Omay
E. Zeynep Erson Omay
Similar to their adult counterparts, the prognosis for pediatric patients with high-grade gliomas remains poor. At time of recurrence, treatment options are limited and remain without consensus. This report describes the genetic findings, obtained from whole-exome sequencing of a pediatric patient with glioblastoma who underwent multiple surgical resections and treatment with standard chemoradiation, as well as a novel recombinant poliovirus vaccine therapy. Strikingly, despite the variety of treatments, there was persistence of a tumor clone, characterized by a deleterious STAG2 mutation, whose deficiency in preclinical studies can cause aneuploidy and aberrant mitotic progression, but remains understudied in the clinical setting. There was near elimination of an EGFR mutated and amplified tumor clone after gross total resection, standard chemoradiation, and poliovirus therapy, followed by the emergence of a persistently STAG2 mutated clone, with rare mutations in PTPN11 and BRAF, the latter composed of a novel deleterious mutation previously not reported in pediatric glioblastoma (p.D594G). This was accompanied by a mutation signature shift towards one characterized by increased DNA damage repair defects, consistent with the known underlying STAG2 deficiency. As such, this case represents a novel report following the clinical and genetic progression of a STAG2 mutated glioblastoma, including treatment with a novel and emerging immunotherapy. Although STAG2 deficiency comprises only a small subset of gliomas, this case adds clinical evidence to existing preclinical data supporting a role for STAG2 mutations in gliomagenesis and resistance to standard therapies.